VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants

Oct 25, 2010, 14:05 ET from thenewsmarket.com from ,Novartis

NEW YORK, Oct. 25 /PRNewswire/ -- See video from Novartis:

http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=d1d3859e-409c-4ac2-93ca-a697ef16d02e  

New Phase III data indicate that Menveo® (Meningococcal Group A, C, W135 and Y conjugate vaccine) demonstrated robust immunogenicity in infants potentially offering protection against four major serogroups of meningococcal disease 1, 3. These data were presented during an oral presentation at the 48th annual meeting of the Infectious Disease Society of America (IDSA) held in Vancouver, Canada. Available media includes video and stills.

About thenewsmarket.com

thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE and ZDF.  

Registered journalists can access video, audio, text, graphics and photos at http://www.thenewsmarket.com  

If you are not already registered, please take a moment to sign up - registration is quick and free: http://www.thenewsmarket.com/registration

SOURCE thenewsmarket.com; Novartis



RELATED LINKS

http://www.thenewsmarket.com